Immunovaccine and IncyteAlign to Treat Patients with Platinum-Sensitive Ovarian Cancer
HALIFAX, NS: Immunovaccine, a clinical stage vaccine and immunotherapy companyhas aligned with Incyte – a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology,to evaluate the combination of Immunovaccine's novel T cell activating immunotherapy, DPX-Survivac, with Incyte's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat.
Immunovaccine and Incyteare planning to evaluate the safety, tolerability and efficacy of the novel combination in platinum-sensitive ovarian cancer patients who are at high risk of recurrence. The investigational new drug (IND) application for the study, which will test the triple combination of DPX-Survivac, epacadostat and low dose oral cyclophosphamide, is expected to be filed this year in the U.S. and Canada and the study is expected to enroll approximately 20 patients.
DPX-Survivac and epacadostat both target pathways that have been linked to cancer progression, namely survivin and IDO1. DPX-Survivac is designed to activate T cells of the immune system to recognize survivin-expressing cancer cells. Epacadostat, on the other hand, is designed to inhibit IDO1-mediated immune suppression in the tumor microenvironment. It is therefore hypothesized that co-administration of these immunotherapies may lead to enhanced anti-tumor effects by both activating the immune system to recognize the cancer and simultaneously weakening its defenses.
"DPX-Survivac and epacadostat represent two exciting classes of immune based therapies with promising activity demonstrated in clinical trials."We believe a multi-pronged immune-based treatment approach may be favorable as an alternative to chemotherapy for recurrent ovarian cancer disease," says Marc Mansour, PhD, Chief Executive Officer,Immunovaccine.
Check out: Top Oncology Solution Companies
By Linda H. Butler, VP of Medical Affairs/CMO/CMIO, Rex...
By Laura Cruz, Global CIO, MDC Partners
By Greg Morrison, SVP & CIO, Cox Enterprises
By Lowell Gilvin, Chief Process Officer, Jabil
By Joe LaFeir, SVP, IS&S (Information Systems & Solutions),...
By Gerri Martin-Flickinger, CIO, Adobe Systems
By Aaron Weis, VP & CIO, Axalta Coating Systems
By Levon Hooks, CIO-Global Corporate Solutions, JLL
By Steve Bein, VP-GIS, Michael Baker International
By Sam Schoelen, Chief Information Technology Officer,...
By Georgios Kyriakopoulos, VP of Equity Research, SunTrust...
By David Sliter, VP & GM of Communications, Media &...
By Julie Stafford, SVP Strategic Consulting, Tangoe
By Dan Adam, CIO, Extreme Networks
By Scott Craig, Vice President of Product Marketing, Lexmark...
By Aaron Gette, CIO, The Bay Club Company
By Dr. Volker G. Hildebrand, Global VP, SAP Hybris
By Meerah Rajavel, CIO, Forcepoint
By Philip Loftus, SVP IT & CIO, SSM Health
By Christy Hartner, SVP, Commerce Bank